VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS

Sakr, Helmy; Otify, Islam; Ayyad, Rezk R; Elwan, Alaa

doi:10.21608/ajps.2023.332170

VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS

Document Type : Original Article

Authors

¹ Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt

² Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt

10.21608/ajps.2023.332170

Abstract

Inhibitors of vascular endothelial growth factor receptor -2 (VEGFR-2) are crucial biological targets for the development of novel anticancer medications. Quinazoline also plays an important role as one of the building elements of numerous anticancer drugs. Thus, a review of the literature on VEGFR-2 inhibitors and Quinazoline-based anticancer medicines has been completed. We introduced VEGFR-2 inhibitors now undergoing clinical evaluation, such as Gefitinib, Erlotinib, Vandetanib, Afatinib, Lenvatinib, Cabozantinib, Sorafenib and Regorafenib in our survey. Additionally, VEGFR-2 inhibitors that are under development were introduced.

Keywords

Main Subjects